Become A Member Event Registration
Close Menu
Chicago Innovation Award Winner

Horizon Pharma

Winner in: 2014
Winning Product: DUEXIS
Winner Category: Chicago Innovation Award
Industry: Healthcare

DUEXIS, a proprietary single-tablet combination of the NSAID ibuprofen and the histamine H2-receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months.

Visit Website

Stay in the know on events &
news for Chicago innovators

Sign up to discover upcoming events and read the latest news about Chicago's innovators.

site by simple edge